Jihui Hao

1.2k total citations
19 papers, 933 citations indexed

About

Jihui Hao is a scholar working on Cancer Research, Oncology and Molecular Biology. According to data from OpenAlex, Jihui Hao has authored 19 papers receiving a total of 933 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Cancer Research, 8 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in Jihui Hao's work include Cancer, Hypoxia, and Metabolism (8 papers), Cancer Cells and Metastasis (4 papers) and Cancer Mechanisms and Therapy (3 papers). Jihui Hao is often cited by papers focused on Cancer, Hypoxia, and Metabolism (8 papers), Cancer Cells and Metastasis (4 papers) and Cancer Mechanisms and Therapy (3 papers). Jihui Hao collaborates with scholars based in China, United States and United Kingdom. Jihui Hao's co-authors include Xiuchao Wang, He Ren, Xiao Zhao, Song Gao, Tiansuo Zhao, He Ren, Shengyu Yang, Chongbiao Huang, Tianjiao Ji and Wei Sun and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Biomaterials.

In The Last Decade

Jihui Hao

18 papers receiving 924 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jihui Hao China	15	405	375	334	228	187	19	933
Linjuan Zeng China	21	583 1.4×	522 1.4×	352 1.1×	180 0.8×	132 0.7×	44	1.2k
Myriam Labelle United States	13	574 1.4×	631 1.7×	235 0.7×	194 0.9×	154 0.8×	19	1.3k
Veronica Finisguerra Belgium	10	471 1.2×	407 1.1×	253 0.8×	443 1.9×	141 0.8×	13	1.2k
Justin Bottsford-Miller United States	16	559 1.4×	591 1.6×	324 1.0×	258 1.1×	103 0.6×	42	1.4k
Xueqian Zhuang China	9	673 1.7×	527 1.4×	395 1.2×	257 1.1×	128 0.7×	10	1.2k
Fangfang Han China	4	304 0.8×	204 0.5×	286 0.9×	129 0.6×	256 1.4×	6	817
Defeng Deng United States	18	703 1.7×	476 1.3×	362 1.1×	280 1.2×	70 0.4×	29	1.3k
André‐René Blaudszun Germany	7	436 1.1×	374 1.0×	245 0.7×	126 0.6×	98 0.5×	13	799
Saket Jain United States	18	455 1.1×	256 0.7×	271 0.8×	195 0.9×	95 0.5×	30	925

Countries citing papers authored by Jihui Hao

Since Specialization

Citations

This map shows the geographic impact of Jihui Hao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jihui Hao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jihui Hao more than expected).

Fields of papers citing papers by Jihui Hao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jihui Hao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jihui Hao. The network helps show where Jihui Hao may publish in the future.

Co-authorship network of co-authors of Jihui Hao

This figure shows the co-authorship network connecting the top 25 collaborators of Jihui Hao. A scholar is included among the top collaborators of Jihui Hao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jihui Hao. Jihui Hao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Liu, Xiaomeng, Zhe Li, Jiaqian Wang, et al.. (2025). A novel platinum(IV) prodrug, gramine-Pt(IV) enhances chemoimmunotherapy by activating cGAS-STING and modulating TGF-β-MHC-I axis. Drug Resistance Updates. 81. 101252–101252. 3 indexed citations

Shao, Zhi‐Ming, Jihui Hao, Shui Wang, et al.. (2025). Dalpiciclib (Dalp) plus endocrine therapy (ET) as adjuvant treatment for HR+/HER2– early breast cancer (BC): The randomized, phase 3, DAWNA-A trial.. Journal of Clinical Oncology. 43(16_suppl). 515–515. 1 indexed citations

Zhang, Ningning, Wei Bai, Wei Zhang, et al.. (2025). Transarterial chemoembolization combined with atezolizumab plus bevacizumab versus transarterial chemoembolization combined with lenvatinib plus sintilimab as first-line therapy for advanced hepatocellular carcinoma.. Journal of Clinical Oncology. 43(16_suppl).

Wu, Liangliang, Yi Ge, Hui Li, et al.. (2022). Genome-wide CRISPR screen identifies MTA3 as an inducer of gemcitabine resistance in pancreatic ductal adenocarcinoma. Cancer Letters. 548. 215864–215864. 17 indexed citations

Zhao, Tiansuo, Di Xiao, Jie Yu, et al.. (2022). ESE3-positive PSCs drive pancreatic cancer fibrosis, chemoresistance and poor prognosis via tumour–stromal IL-1β/NF–κB/ESE3 signalling axis. British Journal of Cancer. 127(8). 1461–1472. 16 indexed citations

Wang, Xiuchao, Jie Dong, Li Jia, et al.. (2017). HIF-2-dependent expression of stem cell factor promotes metastasis in hepatocellular carcinoma. Cancer Letters. 393. 113–124. 35 indexed citations

Xu, Yu, Tai Qin, Jing Li, et al.. (2017). Detection of Circulating Tumor Cells Using Negative Enrichment Immunofluorescence and an In Situ Hybridization System in Pancreatic Cancer. International Journal of Molecular Sciences. 18(4). 622–622. 51 indexed citations

Zhao, Xiao, Keni Yang, Ruifang Zhao, et al.. (2016). Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Biomaterials. 102. 187–197. 224 indexed citations

Li, Feng, Xiao Zhao, Hai Wang, et al.. (2016). Multiple layer-by-layer lipid-polymer hybrid nanoparticles for improved FOLFIRINOX chemotherapy in pancreatic tumor models. Nanomedicine Nanotechnology Biology and Medicine. 12(2). 527–527. 5 indexed citations

10.

Gao, Chuntao, Shasha Li, Tiansuo Zhao, et al.. (2015). SCF, Regulated by HIF-1α, Promotes Pancreatic Ductal Adenocarcinoma Cell Progression. PLoS ONE. 10(3). e0121338–e0121338. 29 indexed citations

11.

Zhao, Xiao, Song Gao, He Ren, et al.. (2014). Hypoxia-Inducible Factor-1 Promotes Pancreatic Ductal Adenocarcinoma Invasion and Metastasis by Activating Transcription of the Actin-Bundling Protein Fascin. Cancer Research. 74(9). 2455–2464. 140 indexed citations

12.

Zhao, Tiansuo, He Ren, Jing Chen, et al.. (2014). LASP1 Is a HIF1α Target Gene Critical for Metastasis of Pancreatic Cancer. Cancer Research. 75(1). 111–119. 84 indexed citations

13.

Wang, Xiuchao, He Ren, Tiansuo Zhao, et al.. (2014). Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. Carcinogenesis. 35(10). 2283–2290. 22 indexed citations

14.

Ren, He, et al.. (2014). The clinical significance and regulation mechanism of hypoxia-inducible factor-1 and miR-191 expression in pancreatic cancer. Tumor Biology. 35(11). 11319–11328. 31 indexed citations

15.

Xu, Yong, Sheng Zhang, Xi Wei, Yi Pan, & Jihui Hao. (2014). Contrast enhanced ultrasonography prediction of cystic renal mass in comparison to histopathology. Clinical Hemorheology and Microcirculation. 58(3). 429–438. 16 indexed citations

16.

Zhao, Tiansuo, He Ren, Li Jia, et al.. (2014). Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma. Oncotarget. 6(4). 2250–2262. 118 indexed citations

17.

Sun, Xiaodong, Min Liu, Jihui Hao, et al.. (2013). Parkin deficiency contributes to pancreatic tumorigenesis by inducing spindle multipolarity and misorientation. Cell Cycle. 12(7). 1133–1141. 54 indexed citations

18.

Zhao, Tiansuo, Song Gao, Xiuchao Wang, et al.. (2012). Hypoxia-Inducible Factor-1α Regulates Chemotactic Migration of Pancreatic Ductal Adenocarcinoma Cells through Directly Transactivating the CX3CR1 Gene. PLoS ONE. 7(8). e43399–e43399. 43 indexed citations

19.

Ren, He, Tiansuo Zhao, Xiuchao Wang, et al.. (2010). Leptin upregulates telomerase activity and transcription of human telomerase reverse transcriptase in MCF-7 breast cancer cells. Biochemical and Biophysical Research Communications. 394(1). 59–63. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact